Probiotics: A possible specific liver drug for non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is and will continue to be a major liver health issue worldwide in the coming decades. There are no leading drug candidates at this point, although there are several promising concepts in drug development. Recent studies have proposed a possible role of inte...

Full description

Saved in:
Bibliographic Details
Published in:Bioscience hypotheses 2009-01, Vol.2 (1), p.54-55
Main Authors: Zheng, Ming-Hua, Xin, Yong-Ning, Li, Hai, Cai, Xiao-Niao, Cui, Yao-Li, Qiu, Li-Xin, Chen, Yong-Ping
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c194t-d4f9b0222243a086dd2db67ce2981cc8b2b0d979ac5c2c214139e80fe505072e3
cites cdi_FETCH-LOGICAL-c194t-d4f9b0222243a086dd2db67ce2981cc8b2b0d979ac5c2c214139e80fe505072e3
container_end_page 55
container_issue 1
container_start_page 54
container_title Bioscience hypotheses
container_volume 2
creator Zheng, Ming-Hua
Xin, Yong-Ning
Li, Hai
Cai, Xiao-Niao
Cui, Yao-Li
Qiu, Li-Xin
Chen, Yong-Ping
description Non-alcoholic fatty liver disease (NAFLD) is and will continue to be a major liver health issue worldwide in the coming decades. There are no leading drug candidates at this point, although there are several promising concepts in drug development. Recent studies have proposed a possible role of intestinal bacterial overgrowth in the development of non-alcoholic steatohepatitis, thus indicated probiotics maybe a potential specific liver drug for NAFLD in the future.
doi_str_mv 10.1016/j.bihy.2008.10.004
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_904486120</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>904486120</sourcerecordid><originalsourceid>FETCH-LOGICAL-c194t-d4f9b0222243a086dd2db67ce2981cc8b2b0d979ac5c2c214139e80fe505072e3</originalsourceid><addsrcrecordid>eNo1kD1PwzAQhj2ARCn8ASZvTAlnx4ljtqriS6pEB5gt27GpK7cOdoqUf0-iwi0nve-jk-5B6I5ASYA0D_tS-91YUoB2CkoAdoEWhNdNQStBr9B1znuAhnLOF2i7TVH7OHiTH_EK9zFnr4PFubfGO29w8D824S6dvrCLCR_jsVDBxF0MU-nUMIz_iM9WZXuDLp0K2d7-7SX6fH76WL8Wm_eXt_VqUxgi2FB0zAkNdBpWKWibrqOdbrixVLTEmFZTDZ3gQpnaUEMJI5WwLThbQw2c2mqJ7s93-xS_TzYP8uCzsSGoo42nLAUw1jaEwkTSM2nS9F2yTvbJH1QaJQE5G5N7ORuTs7E5m4xVv-dFYno</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>904486120</pqid></control><display><type>article</type><title>Probiotics: A possible specific liver drug for non-alcoholic fatty liver disease</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Zheng, Ming-Hua ; Xin, Yong-Ning ; Li, Hai ; Cai, Xiao-Niao ; Cui, Yao-Li ; Qiu, Li-Xin ; Chen, Yong-Ping</creator><creatorcontrib>Zheng, Ming-Hua ; Xin, Yong-Ning ; Li, Hai ; Cai, Xiao-Niao ; Cui, Yao-Li ; Qiu, Li-Xin ; Chen, Yong-Ping</creatorcontrib><description>Non-alcoholic fatty liver disease (NAFLD) is and will continue to be a major liver health issue worldwide in the coming decades. There are no leading drug candidates at this point, although there are several promising concepts in drug development. Recent studies have proposed a possible role of intestinal bacterial overgrowth in the development of non-alcoholic steatohepatitis, thus indicated probiotics maybe a potential specific liver drug for NAFLD in the future.</description><identifier>ISSN: 1756-2392</identifier><identifier>DOI: 10.1016/j.bihy.2008.10.004</identifier><language>eng</language><ispartof>Bioscience hypotheses, 2009-01, Vol.2 (1), p.54-55</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c194t-d4f9b0222243a086dd2db67ce2981cc8b2b0d979ac5c2c214139e80fe505072e3</citedby><cites>FETCH-LOGICAL-c194t-d4f9b0222243a086dd2db67ce2981cc8b2b0d979ac5c2c214139e80fe505072e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Zheng, Ming-Hua</creatorcontrib><creatorcontrib>Xin, Yong-Ning</creatorcontrib><creatorcontrib>Li, Hai</creatorcontrib><creatorcontrib>Cai, Xiao-Niao</creatorcontrib><creatorcontrib>Cui, Yao-Li</creatorcontrib><creatorcontrib>Qiu, Li-Xin</creatorcontrib><creatorcontrib>Chen, Yong-Ping</creatorcontrib><title>Probiotics: A possible specific liver drug for non-alcoholic fatty liver disease</title><title>Bioscience hypotheses</title><description>Non-alcoholic fatty liver disease (NAFLD) is and will continue to be a major liver health issue worldwide in the coming decades. There are no leading drug candidates at this point, although there are several promising concepts in drug development. Recent studies have proposed a possible role of intestinal bacterial overgrowth in the development of non-alcoholic steatohepatitis, thus indicated probiotics maybe a potential specific liver drug for NAFLD in the future.</description><issn>1756-2392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNo1kD1PwzAQhj2ARCn8ASZvTAlnx4ljtqriS6pEB5gt27GpK7cOdoqUf0-iwi0nve-jk-5B6I5ASYA0D_tS-91YUoB2CkoAdoEWhNdNQStBr9B1znuAhnLOF2i7TVH7OHiTH_EK9zFnr4PFubfGO29w8D824S6dvrCLCR_jsVDBxF0MU-nUMIz_iM9WZXuDLp0K2d7-7SX6fH76WL8Wm_eXt_VqUxgi2FB0zAkNdBpWKWibrqOdbrixVLTEmFZTDZ3gQpnaUEMJI5WwLThbQw2c2mqJ7s93-xS_TzYP8uCzsSGoo42nLAUw1jaEwkTSM2nS9F2yTvbJH1QaJQE5G5N7ORuTs7E5m4xVv-dFYno</recordid><startdate>200901</startdate><enddate>200901</enddate><creator>Zheng, Ming-Hua</creator><creator>Xin, Yong-Ning</creator><creator>Li, Hai</creator><creator>Cai, Xiao-Niao</creator><creator>Cui, Yao-Li</creator><creator>Qiu, Li-Xin</creator><creator>Chen, Yong-Ping</creator><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>200901</creationdate><title>Probiotics: A possible specific liver drug for non-alcoholic fatty liver disease</title><author>Zheng, Ming-Hua ; Xin, Yong-Ning ; Li, Hai ; Cai, Xiao-Niao ; Cui, Yao-Li ; Qiu, Li-Xin ; Chen, Yong-Ping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c194t-d4f9b0222243a086dd2db67ce2981cc8b2b0d979ac5c2c214139e80fe505072e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zheng, Ming-Hua</creatorcontrib><creatorcontrib>Xin, Yong-Ning</creatorcontrib><creatorcontrib>Li, Hai</creatorcontrib><creatorcontrib>Cai, Xiao-Niao</creatorcontrib><creatorcontrib>Cui, Yao-Li</creatorcontrib><creatorcontrib>Qiu, Li-Xin</creatorcontrib><creatorcontrib>Chen, Yong-Ping</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Bioscience hypotheses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zheng, Ming-Hua</au><au>Xin, Yong-Ning</au><au>Li, Hai</au><au>Cai, Xiao-Niao</au><au>Cui, Yao-Li</au><au>Qiu, Li-Xin</au><au>Chen, Yong-Ping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Probiotics: A possible specific liver drug for non-alcoholic fatty liver disease</atitle><jtitle>Bioscience hypotheses</jtitle><date>2009-01</date><risdate>2009</risdate><volume>2</volume><issue>1</issue><spage>54</spage><epage>55</epage><pages>54-55</pages><issn>1756-2392</issn><abstract>Non-alcoholic fatty liver disease (NAFLD) is and will continue to be a major liver health issue worldwide in the coming decades. There are no leading drug candidates at this point, although there are several promising concepts in drug development. Recent studies have proposed a possible role of intestinal bacterial overgrowth in the development of non-alcoholic steatohepatitis, thus indicated probiotics maybe a potential specific liver drug for NAFLD in the future.</abstract><doi>10.1016/j.bihy.2008.10.004</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1756-2392
ispartof Bioscience hypotheses, 2009-01, Vol.2 (1), p.54-55
issn 1756-2392
language eng
recordid cdi_proquest_miscellaneous_904486120
source ScienceDirect Freedom Collection 2022-2024
title Probiotics: A possible specific liver drug for non-alcoholic fatty liver disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T03%3A05%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Probiotics:%20A%20possible%20specific%20liver%20drug%20for%20non-alcoholic%20fatty%20liver%20disease&rft.jtitle=Bioscience%20hypotheses&rft.au=Zheng,%20Ming-Hua&rft.date=2009-01&rft.volume=2&rft.issue=1&rft.spage=54&rft.epage=55&rft.pages=54-55&rft.issn=1756-2392&rft_id=info:doi/10.1016/j.bihy.2008.10.004&rft_dat=%3Cproquest_cross%3E904486120%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c194t-d4f9b0222243a086dd2db67ce2981cc8b2b0d979ac5c2c214139e80fe505072e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=904486120&rft_id=info:pmid/&rfr_iscdi=true